SCHEMBL8397975

SCHEMBL8397975

CCOC(=O)C(OS(=O)(=O)C(F)(F)F)C(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
MAPT P10636 2/20 0.34
HSD17B10 Q99714 2/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PIN1 Q13526 1/20 0.33
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
ALDH1A1 P00352 4/20 0.31
LMNA P02545 1/20 0.30
ATM Q13315 1/20 0.30
CXCR2 P25025 1/20 0.30
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP3 P08254 1/20 0.30
MMP9 P14780 1/20 0.30
MMP13 P45452 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8397971 1.00 POLB (0.36) POLBMAPTHSD17B10HTTSMN1; SMN2
SCHEMBL1576184 0.82 CA14 (0.40) SMN1; SMN2CA12CA1CA2CA9
SCHEMBL701746 0.82 POLB (0.38) POLBMAPTHSD17B10HTTSMN1; SMN2
SCHEMBL324715 0.82 POLB (0.38) POLBMAPTHSD17B10HTTSMN1; SMN2
SCHEMBL324716 0.82 POLB (0.38) POLBMAPTHSD17B10HTTSMN1; SMN2
SCHEMBL8400666 0.80 MMP1 (0.38) CA1CA2CXCR2MMP1MMP2
SCHEMBL29205828 0.80 MMP1 (0.38) CA1CA2CXCR2MMP1MMP2
SCHEMBL9773131 0.79 MMP8 (0.43) POLBMAPTHSD17B10HTTSMN1; SMN2
SCHEMBL31153798 0.79 CA12 (0.34) CA12CA1CA2CXCR2
SCHEMBL5551942 0.79 CA12 (0.34) CA12CA1CA2CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2978756-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES Bayer Pharma AG (DE) 2019-03-27 EP disclosed
US-10183932-B2 Substituted oxopyridine derivatives and use thereof cardiovascular disorders BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-22 US disclosed
US-20180086742-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-03-29 US disclosed
US-9822102-B2 Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-21 US disclosed
US-20160368903-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-22 US disclosed
US-9434690-B2 Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-06 US disclosed
US-20160052884-A1 Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 US disclosed
EP-2978756-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS Bayer Pharma Aktiengesellschaft (DE) 2016-02-03 EP disclosed
WO-2014154794-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-10-02 WO disclosed
EP-0918757-A1 8-HYDROCARBYL SUBSTITUTED BENZODIZOCINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN KINASE C (=PKC) MODULATORS GEORGETOWN UNIVERSITY (US) 1999-06-02 EP disclosed
WO-1997043268-A1 8-HYDROCARBYL SUBSTITUTED BENZODIZOCINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN KINASE C (=PKC) MODULATORS GEORGETOWN UNIVERSITY (US) 1997-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183932-B2 Substituted oxopyridine derivatives and use thereof cardiovascular disorders OGFOD1, VASP, PNPO POLB 1422/4885MAPT 4575/4885HSD17B10 2895/4885
US-20160052884-A1 Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders OGFOD1, PNPO, VASP POLB 1268/4885MAPT 4608/4885HSD17B10 3135/4885
US-20180086742-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS OGFOD1, PNPO, VASP POLB 1268/4885MAPT 4608/4885HSD17B10 3135/4885
US-20160368903-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS OGFOD1, PNPO, VASP POLB 1268/4885MAPT 4608/4885HSD17B10 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.